| Literature DB >> 25525422 |
Har Lal Singh1, Jangbhadur Singh1.
Abstract
New series of organotin(IV) complexes and Schiff bases derived from amino acids have been designed and synthesized from condensation of 1H-indole-2,3-dione, 5-chloro-1H-indole-2,3-dione, and α-amino acids (phenylalanine, isoleucine, and glycine). All compounds are characterized by elemental analyses, molar conductance measurements, and molecular weight determinations. Bonding of these complexes is discussed in terms of their UV-visible, infrared, and nuclear magnetic resonance ((1)H, (13)C, and (119)Sn NMR) spectral studies. The results suggest that Schiff bases behave as monobasic bidentate ligands and coordinate with dibutyltin(IV) in octahedral geometry according to the general formula [Bu2Sn(L)2]. Elemental analyses and NMR spectral data of the ligands with their dibutyltin(IV) complexes agree with their proposed distorted octahedral structures. Few representative compounds are tested for their in vitro antibacterial activity against Gram-positive (B. cereus, Staphylococcus spp.) and Gram-negative (E. coli, Klebsiella spp.) bacteria. The results show that the dibutyltin complexes are more reactive with respect to their corresponding Schiff base ligands.Entities:
Year: 2014 PMID: 25525422 PMCID: PMC4265522 DOI: 10.1155/2014/716578
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Analytical and physical data of the organotin(IV) complexes.
| C. number | Reactants | Molar ratio | Products & colour | M.P. °C (d) | Yield (%) | Elemental analysis found (calcd.) |
Mol. Wt. | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Metal | Ligands | %Sn | %C | %H | %N | ||||||
| Bu2Sn(L1)2 | Bu2SnO | C17H14N2O3 | 1 : 2 | C42H44N4O6Sn | 164 | 94 | 14.35(14.49) | 61.30(61.55) | 5.44(5.41) | 6.72(6.84) | 824.55(819.53) |
|
| |||||||||||
| Bu2Sn(L2)2 | Bu2SnO | C14H16N2O3 | 1 : 2 | C36H48N4O6Sn | 262 | 79.14 | 15.84(15.80) | 57.50(57.54) | 6.38(6.44) | 7.56(7.46) | 742.19(751.50) |
|
| |||||||||||
| Bu2Sn(L3)2 | Bu2SnO | C10H8N2O3 | 1 : 2 | C28H32N4O6Sn | 174 | 76.81 | 18.43(18.57) | 52.45(52.61) | 5.00(5.05) | 8.65(8.76) | 630.88(639.29) |
|
| |||||||||||
| Bu2Sn(L4)2 | Bu2SnO | C17H13ClN2O3 | 1 : 2 | C42H42Cl2N4O6Sn | 210 | 72.39 | 13.03(13.36) | 56.84(56.78) | 4.73(4.76) | 6.39(6.31) | 872.54(888.42) |
|
| |||||||||||
| Bu2Sn(L5)2 | Bu2SnO | C14H15ClN2O3 | 1 : 2 | C36H46Cl2N4O6Sn | 270 | 68.29 | 14.34(14.47) | 52.59(52.71) | 5.60(5.65) | 6.70(6.83) | 831.57(820.38) |
|
| |||||||||||
| Bu2Sn(L6)2 | Bu2SnO | C10H7ClN2O3 | 1 : 2 | C28H30Cl2N4O6Sn | 180–184 | 71.72 | 16.84(16.76) | 47.41(47.49) | 4.25(4.27) | 7.85(7.91) | 716.67(708.18) |
Scheme 1Representative equation illustrating the formation of dibutyltin(IV) complexes.
Important IR spectral data (cm−1) of Schiff bases and their corresponding organotin(IV) complexes.
| Compounds |
|
|
|
|
| Δ |
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| L1H | 3090–2740 br | 1620 s | 1728 s | — | — | — | — | — | — |
| Bu2Sn(L1)2 | — | 1610 s | 1722 s | 1590 vs | 1325 s | 265 | 540 w | 430 m | 622 m |
| L2H | 3100–2740 br | 1625 s | 1730 s | — | — | — | — | — | — |
| Bu2Sn(L2)2 | — | 1612 s | 1726 s | 1605 m | 1333 m | 272 | 545 m | 426 s | 640 m |
| L3H | 3090–2750 br | 1630 s | 1720 s | — | — | — | — | — | — |
| Bu2Sn(L3)2 | — | 1616 s | 1722 s | 1601 s | 1332 m | 268 | 552 m | 425 m | 630 m |
| L4H | 3110–2750 br | 1622 s | 1735 s | — | — | — | — | — | — |
| Bu2Sn(L4)2 | — | 1605 s | 1732 s | 1608 s | 1330 m | 278 | 545 s | 420 w | 635 m |
| L5H | 3080–2730 br | 1630 s | 1735 s | — | — | — | — | — | — |
| Bu2Sn(L5)2 | — | 1612 s | 1734 s | 1595 vs | 1326 s | 269 | 540 w | 425 w | 625 m |
| L6H | 3109–2730 br | 1622 s | 1725 s | — | — | — | — | — | — |
| Bu2Sn(L6)2 | — | 1610 s | 1728 s | 1610 vs | 1340 vs | 270 | 544 w | 432 m | 632 m |
br: broad, vs: very sharp, v: sharp, m: medium, and w: weak.
1H NMR spectral dataa of the ligands and their corresponding organotin(IV) complexes.
| Compounds | Chemical Shift ( |
|---|---|
| L1H | 11.50 (s, 1H, COO |
|
| |
| Bu2Sn(L1)2 | 4.21 (s, 1H, N–C |
|
| |
| L2H | 11.39 (s, 1H, COO |
|
| |
| Bu2Sn(L2)2 | 3.98 (d, 1H, N–C |
|
| |
| L3H | 11.28 (s, 1H, COOH), 4.30 (s, 2H, N–C |
|
| |
| Bu2Sn(L3)2 | 4.38 (s, 2H, N–C |
|
| |
| L4H | 11.42 (s, 1H, COO |
|
| |
| Bu2Sn(L4)2 | 4.02 (t, 1H, N–C |
|
| |
| L5H | 11.42 (s, 1H, COO |
|
| |
| Bu2Sn(L5)2 | 4.01 (d, 1H, N–C |
|
| |
| L6H | 11.35 (s, 1H, COO |
|
| |
| Bu2Sn(L6)2 | 4.40 (s, 2H, N–C |
aChemical shift (δ) in ppm: Multiplicity is given as: s = singlet, d = doublet, t = triplet, q = quartet, m = complex pattern, br = broad.
13C NMR spectral data of the ligands and their corresponding organotin(IV) complexes.
| Compounds | Chemical shift in ( | |||||
|---|---|---|---|---|---|---|
| COOH | CH | C=N | CH2/CH3 | Aromatic carbons | Sn– | |
| L1H | 176.8 | 67.8 | 163.4 | 38.2 | 149.2, 135.8, 133.0, 128.6, 127.5, 126.3, 124.6, 122.9, 120.1 | — |
|
| ||||||
| Bu2Sn(L1)2 | 185.4 | 65.7 | 155.2 | 39.4 | 150.0, 136.1, 132.6, 128.2, 127.1, 126.5, 124.4, 123.3, 120.2 | C- |
|
| ||||||
| L2H | 178.5 | 65.7 | 162.4 | 16.3, 21.3 | 145.8, 133.2, 130.5, 126.2, 124.0, 119.3 | — |
|
| ||||||
| Bu2Sn(L2)2 | 184.9 | 66.2 | 154.6 | 17.4, 22.1 | 146.2, 132.9, 130.8, 126.54, 124.3, 120.1 | C- |
|
| ||||||
| L3H | 176.1 | — | 163.6 | 52.4 | 148.5, 131.0, 129.8, 125.3, 122.9, 119.1 | — |
|
| ||||||
| Bu2Sn(L3)2 | 183.7 | — | 154.5 | 58.3 | 149.0, 132.5, 129.6, 125.7, 123.4, 119.6 | C- |
|
| ||||||
| L4H | 178.5 | 65.7 | 162.4 | 39.1 | 150.2, 136.1, 132.8, 129.5, 127.3, 126.4, 123.2, 122.4, 119.8 | — |
|
| ||||||
| Bu2Sn(L4)2 | 184.5 | 66.2 | 154.5 | 38.7 | 149.5, 135.7, 132.1, 130.4, 126.9, 126.2, 123.5, 122.1, 120.3 | C- |
|
| ||||||
| L5H | 177.5 | 66.2 | 163.1 | 17.3, 20.5 | 147.7, 132.8, 131.3, 126.6, 123.8, 120.3 | — |
|
| ||||||
| Bu2Sn(L5)2 | 184.1 | 67.4 | 153.8 | 18.0, 20.2 | 148.1, 132.4, 129.7, 126.5, 124.0, 120.2 | C- |
|
| ||||||
| L6H | 176.9 | — | 162.9 | 55.4 | 149.5, 132.8, 128.9, 125.7, 123.0, 120.3 | — |
|
| ||||||
| Bu2Sn(L6)2 | 182.8 | — | 155.4 | 56.1 | 148.2, 133.1, 128.5, 125.8, 122.7, 120.5 | C- |
Figure 1Structure of diorganotin(IV) complexes.
X-ray powder diffraction data for compounds (L1H) and (L2H).
| S. number | 2 | “ | Intensity (count) | FWHM |
|
|---|---|---|---|---|---|
| L1H | |||||
| 1 | 13.517 | 6.54547 | 385.6 | 0.5425 | 25.381 |
| 2 | 14.936 | 5.92655 | 482.3 | 0.4308 | 31.912 |
| 3 | 16.873 | 5.25031 | 216.5 | 0.7307 | 18.770 |
| 4 | 21.492 | 4.13128 | 323.9 | 0.7307 | 18.643 |
| 5 | 22.046 | 4.02874 | 453.9 | 0.6139 | 22.169 |
| 6 | 22.521 | 3.94474 | 289.4 | 0.6139 | 22.151 |
| 7 | 24.025 | 3.70113 | 301.8 | 0.6139 | 22.091 |
| 8 | 24.805 | 3.58649 | 162.8 | 0.6139 | 22.059 |
| 9 | 25.067 | 3.54964 | 205.2 | 0.6139 | 22.047 |
| 10 | 26.359 | 3.37851 | 150.7 | 0.6139 | 21.991 |
| 11 | 27.324 | 3.26131 | 228.2 | 0.486 | 27.722 |
| 12 | 28.440 | 3.13581 | 217.5 | 0.7166 | 18.756 |
| 13 | 32.024 | 2.79258 | 112.5 | 0.7166 | 18.598 |
|
| |||||
| L2H | |||||
| 1 | 11.495 | 7.69156 | 128 | 0.3461 | 39.860 |
| 2 | 13.137 | 6.73368 | 236.3 | 0.3806 | 36.191 |
| 3 | 14.870 | 5.95279 | 807.9 | 0.2844 | 48.343 |
| 4 | 16.683 | 5.30969 | 228.6 | 0.3597 | 38.139 |
| 5 | 21.263 | 4.17518 | 222.4 | 0.3597 | 37.885 |
| 6 | 22.035 | 4.03068 | 286.1 | 0.5986 | 22.736 |
| 7 | 23.706 | 3.75021 | 263.9 | 0.5544 | 24.476 |
| 8 | 24.902 | 3.57273 | 521.9 | 0.3499 | 38.695 |
| 9 | 26.232 | 3.39454 | 156.1 | 0.3499 | 38.593 |
| 10 | 27.114 | 3.28608 | 717.3 | 0.2874 | 46.899 |
| 11 | 31.637 | 2.82587 | 144.2 | 0.4665 | 28.597 |
| 12 | 37.570 | 2.3921 | 84.3 | 0.6166 | 21.289 |
* D: crystallite size (in Å) and d: lattice spacing.
Figure 2X-ray powder diffraction patterns of the compound [L1H].
Figure 3X-ray powder diffraction patterns of the compound [L2H].
Important bond lengths of compound [Bu2Sn(L2)2].
| S. number | Atoms | Actual (Å) | Optimal (Å) |
|---|---|---|---|
| 1 | Sn(1)–C(44) | 2.2339 | 2.1620 |
| 2 | Sn(1)–C(47) | 2.2064 | 2.1620 |
| 3 | N(9)–Sn(1) | 2.1050 | — |
| 4 | N(5)–Sn(1) | 2.1010 | — |
| 5 | Sn(1)–C(44) | 2.2339 | 2.1620 |
| 6 | Sn(1)–O(6) | 2.0644 | — |
| 7 | O(6)–C(7) | 1.3666 | 1.3380 |
| 8 | Sn(1)–O(2) | 2.0581 | — |
| 9 | O(2)–C(3) | 1.3639 | 1.3380 |
| 10 | Sn(1)–C(47) | 2.2064 | 2.1620 |
| 11 | N(5)–C(14) | 2.1680 | 1.2600 |
| 12 | C(4)–N(5) | 1.4923 | 1.4700 |
Important bond angles of compound [Bu2Sn(L2)2].
| S. number | Atoms | Actual (°) |
|---|---|---|
| 1 | C(47)–Sn(1)–C(44) | 117.1540 |
| 2 | C(47)–Sn(1)–N(5) | 85.7227 |
| 3 | C(47)–Sn(1)–N(9) | 124.3910 |
| 4 | C(47)–Sn(1)–O(6) | 68.5077 |
| 5 | C(47)–Sn(1)–O(2) | 141.0197 |
| 6 | C(44)–Sn(1)–N(5) | 80.4837 |
| 7 | C(44)–Sn(1)–N(9) | 78.7094 |
| 8 | C(44)–Sn(1)–O(6) | 138.6752 |
| 9 | C(44)–Sn(1)–O(2) | 88.6745 |
| 10 | N(5)–Sn(1)–N(9) | 148.9524 |
| 11 | N(5)–Sn(1)–O(6) | 139.5356 |
| 12 | N(5)–Sn(1)–O(2) | 69.4566 |
| 13 | N(9)–Sn(1)–O(6) | 67.5865 |
| 14 | N(9)–Sn(1)–O(2) | 87.2268 |
| 15 | O(6)–Sn(1)–O(2) | 112.0005 |
Figure 43D molecular structure of Bu2Sn(L2)2.
Antibacterial activity of ligands and their organotin(IV) complexes.
| Schiff bases/complexes | Zone of inhibition (mm) | |||||||
|---|---|---|---|---|---|---|---|---|
| Gram-negative | Gram-positive | |||||||
|
|
|
|
| |||||
| 500 ppm | 200 ppm | 500 ppm | 200 ppm | 500 ppm | 200 ppm | 500 ppm | 200 ppm | |
| L2H | 18 ± 0.6 | 15 ± 0.1 | 22 ± 0.6 | 17 ± 0.1 | 14 ± 0.2 | 12 ± 0.9 | 23 ± 0.2 | 20 ± 0.7 |
| Bu2Sn(L2)2 | 25 ± 0.7 | 22 ± 0.4 | 30 ± 0.3 | 26 ± 0.8 | 20 ± 0.7 | 18 ± 0.4 | 30 ± 0.1 | 25 ± 0.5 |
| L3H | 12 ± 0.1 | 10 ± 0.3 | 15 ± 0.1 | 13 ± 0.6 | 20 ± 0.1 | 18 ± 0.6 | 21 ± 0.5 | 18 ± 0.6 |
| Bu2Sn(L3)2 | 16 ± 0.4 | 15 ± 0.6 | 18 ± 0.5 | 16 ± 0.4 | 32 ± 0.1 | 28 ± 0.3 | 30 ± 0.2 | 27 ± 0.2 |
| L5H | 14 ± 0.3 | 12 ± 0.9 | 15 ± 0.2 | 12 ± 0.1 | 24 ± 0.6 | 20 ± 0.1 | 19 ± 0.1 | 17 ± 0.1 |
| Bu2Sn(L5)2 | 20 ± 0.5 | 18 ± 0.1 | 20 ± 0.5 | 18 ± 0.5 | 28 ± 0.3 | 23 ± 0.4 | 29 ± 0.4 | 25 ± 0.6 |
| L6H | 11 ± 0.3 | 13 ± 0.2 | 10 ± 0.1 | 8 ± 0.5 | 20 ± 0.5 | 17 ± 0.8 | 18 ± 0.6 | 15 ± 0.2 |
| Bu2Sn(L6)2 | 16 ± 0.2 | 15 ± 0.5 | 11 ± 0.8 | 10 ± 0.9 | 24 ± 0.9 | 19 ± 0.5 | 20 ± 0.1 | 18 ± 0.4 |
| Streptomycin | 28 ± 0.1 | 23 ± 0.3 | 26 ± 0.3 | 20 ± 0.5 | 26 ± 0.8 | 22 ± 0.1 | 32 ± 0.1 | 26 ± 0.3 |
| DMSO | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |